On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that new clinical data will be presented in three oral ...

Beam Therapeutics Inc. disclosed that one patient died in the phase I/II trial testing BEAM-101 in sickle cell disease (SCD), though the case of respiratory failure was determined by the investigator ...

Raymond James downgraded Editas Medicine (EDIT) to Market Perform from Outperform without a price target The firm cites the company’s ...

Editas Medicine (EDIT) has been downgraded to market perform from outperform by Raymond James due in part to extended ...

Older patients with MDS often receive reduced intensity conditioning regimens. These regimens tend to be less aggressive than traditional myeloablative therapies. The specific regimens mentioned ...

Transplants were conducted after either myeloablative conditioning (n = 1752) or reduced intensity conditioning (n = 759). The primary outcome of the study was 2-year OS, while secondary outcomes ...

During the peer-review process the editor and reviewers write an eLife assessment that summarises the significance of the findings reported in the article (on a scale ranging from landmark to useful) ...